| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
BBD does not have a specific biological target as a drug; rather, it functions as a fluorescent probe and staining reagent. As a benzoxadiazole derivative, BBD has a role as a fluorochrome and is used to label and detect biomolecules. The compound's fluorescence properties allow it to bind to nucleic acids and proteins, enabling visualization and quantification in various biochemical and cellular assays. BBD is a cell-permeant nucleic acid stain that can be used to detect DNA and RNA in cells. Its mode of action involves intercalation or binding to nucleic acids, resulting in fluorescence enhancement upon binding. The compound is used as a molecular probe to study protein-nucleic acid interactions, enzyme activities, and cellular processes.
|
|---|---|
| ln Vitro |
In vitro studies of BBD focus on its fluorescent properties and its use as a biochemical probe. The compound exhibits strong fluorescence that is enhanced upon binding to nucleic acids or proteins, making it a sensitive detection reagent. BBD has been used as a fluorogenic substrate in enzyme assays, where enzymatic activity is monitored by changes in fluorescence. The compound is also used as a labeling reagent for the detection of amines, thiols, and other functional groups in biochemical samples. BBD's fluorescence properties, including excitation and emission spectra, have been characterized, allowing its use in various fluorescence-based applications. The compound is stable under typical laboratory conditions and can be used in a wide range of assay formats. In cellular studies, BBD is used as a cell-permeant nucleic acid stain for flow cytometry and fluorescence microscopy applications. The compound can penetrate cell membranes and bind to nucleic acids within cells, enabling the visualization and quantification of DNA and RNA content. BBD is used to distinguish between different cell types based on their nucleic acid content and to assess cell viability and proliferation. In flow cytometry, BBD staining allows for the identification and sorting of cell populations. The compound's fluorescence is enhanced upon binding to nucleic acids, providing bright and specific staining. BBD is also used in combination with other fluorescent probes for multiplexed analysis of cellular parameters. Its cell-permeability and nucleic acid-binding properties make it a useful tool for cell biology research.
|
| ln Vivo |
In vivo studies of BBD are limited, as the compound is primarily used as a research reagent for in vitro and cellular applications rather than as a therapeutic or diagnostic agent. However, fluorescent probes like BBD may be used in animal models for imaging applications, such as tracking cells or biomolecules in vivo. In such studies, BBD-labeled cells or molecules are administered to animals, and their distribution and fate are monitored by fluorescence imaging. The compound's fluorescence properties enable sensitive detection in biological samples. No extensive in vivo pharmacological or toxicological studies have been reported for BBD.
|
| Enzyme Assay |
For fluorescence characterization assays, BBD is dissolved in appropriate solvent (e.g., DMSO, methanol, or aqueous buffer) and its absorption and emission spectra are measured using a UV-Vis spectrophotometer and fluorescence spectrometer, respectively. Excitation and emission maxima are determined. For nucleic acid binding studies, BBD is incubated with purified DNA or RNA in assay buffer (e.g., 10 mM Tris-HCl, pH 7.4, 100 mM NaCl) at varying concentrations (0.1-10 µM). Fluorescence intensity is measured at the emission maximum, and the fluorescence enhancement upon nucleic acid binding is calculated. Binding affinity (Kd) is determined by fitting fluorescence titration data to a binding isotherm. For enzyme assays, BBD-labeled substrates are used, and enzymatic activity is monitored by following changes in fluorescence over time. For labeling reactions, BBD is reacted with amine- or thiol-containing compounds under appropriate conditions, and the labeled products are analyzed by HPLC or mass spectrometry.
|
| Cell Assay |
For cellular staining, cells are cultured in appropriate medium and harvested by trypsinization. Cells are washed with PBS and resuspended in staining buffer (e.g., PBS with 1% BSA) at a density of 1-5 × 10⁶ cells/ml. BBD is added to the cell suspension at a final concentration of 0.1-10 µM and incubated at 37°C for 15-30 minutes in the dark. Stained cells are washed twice with PBS to remove unbound dye. For flow cytometry analysis, stained cells are analyzed using a flow cytometer equipped with an appropriate laser line (e.g., 488 nm) and fluorescence detectors. Fluorescence intensity is measured in the appropriate channel (e.g., FL2 or FL3). For fluorescence microscopy, stained cells are placed on glass slides or chamber slides and imaged using a fluorescence microscope. For cell viability assessment, BBD staining is used in combination with other viability dyes (e.g., propidium iodide) to distinguish live from dead cells.
|
| Animal Protocol |
No standard in vivo protocols exist specifically for BBD, as it is primarily a research reagent for in vitro applications. If used in animal studies, BBD would likely be administered intravenously or intraperitoneally to mice at doses determined from preliminary studies. Tissues and organs would be collected at various time points and processed for fluorescence imaging or homogenized for fluorometric analysis. Biodistribution would be assessed by measuring fluorescence in tissue homogenates or by imaging whole animals using an in vivo imaging system. However, such studies are not typical for this compound, and no specific dosing or administration protocols are reported in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for BBD are not available, as the compound is used as a research reagent rather than a therapeutic agent. If used in vivo, BBD would be expected to have distribution to various tissues due to its cell-permeability. The compound's metabolism and excretion would depend on its chemical structure, likely involving hepatic metabolism and biliary or renal clearance. However, no dedicated ADME studies have been reported for BBD. The compound is primarily used in vitro and is not intended for in vivo pharmacokinetic characterization.
|
| Toxicity/Toxicokinetics |
Toxicological data for BBD are limited, as the compound is used as a research reagent and not as a therapeutic agent. The compound is generally considered to have low toxicity at the concentrations used for staining and labeling applications (typically 0.1-10 µM). No acute toxicity, mutagenicity, or carcinogenicity data have been reported. As with all chemical reagents, appropriate safety precautions should be taken when handling BBD, including the use of personal protective equipment (gloves, lab coat, safety glasses) and work in a well-ventilated area. The compound should be handled according to standard laboratory safety protocols.
|
| Additional Infomation |
7-Benzylamino-4-nitrobenzo-2-oxa-1,3-diazole is a benzoxadiazole. It can be used as a fluorescent dye.
BBD (4-benzylamino-7-nitrobenzofurazan) is a fluorogenic chromophore belonging to the benzoxadiazole class of compounds. It is used as a fluorescent labeling reagent and biochemical probe for the detection and quantification of various analytes, including nucleic acids and proteins. BBD is a cell-permeant nucleic acid stain that can be used in flow cytometry and fluorescence microscopy applications. The compound exhibits intense fluorescence that is enhanced upon binding to nucleic acids or proteins, making it a sensitive detection reagent. BBD is also known as NSC240867. Its molecular formula is C₁₃H₁₀N₄O₃ with a molecular weight of 270.24. The compound is commonly used in biochemical research for studying protein interactions, enzyme activities, and as a molecular probe. BBD has not entered clinical trials and is strictly for research use only. |
| Molecular Formula |
C13H10N4O3
|
|---|---|
| Molecular Weight |
270.2435
|
| Exact Mass |
270.075
|
| CAS # |
18378-20-6
|
| PubChem CID |
87615
|
| Appearance |
Brown to orange solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
468.0±55.0 °C at 760 mmHg
|
| Melting Point |
206-209ºC
|
| Flash Point |
236.9±31.5 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.723
|
| LogP |
3.05
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
343
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
GZFKJMWBKTUNJS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H10N4O3/c18-17(19)11-7-6-10(12-13(11)16-20-15-12)14-8-9-4-2-1-3-5-9/h1-7,14H,8H2
|
| Chemical Name |
N-benzyl-4-nitro-2,1,3-benzoxadiazol-7-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 34 mg/mL (~125.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7004 mL | 18.5021 mL | 37.0041 mL | |
| 5 mM | 0.7401 mL | 3.7004 mL | 7.4008 mL | |
| 10 mM | 0.3700 mL | 1.8502 mL | 3.7004 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
